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Introduction
, with neutrophils being particularly preferred in mice [15] . B. pseudomallei 70 has multiple virulence factors that support this lifestyle; the intracellular niche 71 provides the organism with protection against the host immune system. This is 72 particularly important as the humoral response is the best correlate of protection 73 in vaccination studies [16] . The intracellular location also makes antibiotic 74 chemotherapy more challenging as compounds must cross an additional 75 biological membrane. 76 77 B. pseudomallei is naturally resistant to most clinically used antibiotics, 78
including some of the more recently developed antibiotics [1, 17] . The most 79 effective treatment is with an intensive phase of at least two weeks intravenous 80 ceftazidime and/or meropenem [18] ; increasing this phase to at least four weeks 81 has reduced the rate of relapse. However, in many lower income settings 82 alternative eradication regimes are used that have increased relapse rates [19] . 83
When cultured to stationary phase or in hypoxic conditions, most Burkholderia 84 species show a high subpopulation that are recalcitrant to antibiotic treatment 85 [20] . This observation is believed to mimic behavior in vivo, with B. 86 pseudomallei surviving in biofilms or intracellular niches where cellular 87 conditions promote antibiotic tolerance [21] [22] [23] . This can then lead to recurrent 88 or latent forms of the disease and the relapse of infections in humans where 89 longer term antibiotic treatment is not administered [24] . Although significant 90 progress has been made towards a melioidosis vaccine, candidates have yet to 91 enter clinical trials [25, 26] . 92 5 This presents an urgent unmet need for affordable novel drugs that supplement 93 current effective therapeutics to reduce the cost and duration of treatment and 94 to prevent relapse of infection [18, 27] . We hypothesized that small molecules 95 could act as co-therapies that could be administered alongside front-line 96 treatments with the aim of reducing the rates of recurrent infection. We aimed to 97 develop an assay that would allow rapid screening of a compound library to 98 identify and validate such compounds, as a step towards a potential therapy. As 99 B. pseudomallei is a Containment Level 3 bacterium, Burkholderia thailandensis 100 was selected for this study. This is a close relative of the pathogenic B. 101 pseudomallei with over 85% gene conservation [28] . As B. thailandensis does 102 not cause disease in immunocompetent humans [28] [29] [30] , it has been classified 103 as a Containment Level 2 bacterium, and is commonly used as a surrogate for 104 B. pseudomallei. Previous studies have shown that approximately 0.1% of B. 105 thailandensis cells survive for 24 hours following treatment with 100X MIC of the 106 front-line antibiotic ceftazidime in vitro [20] . 107 108 A phenotypic assay using the cell viability reagent PrestoBlue™ was used to 109 screen compounds from a diversity library containing nearly 5,000 core 110 fragments [31] at the Drug Discovery Unit (DDU) in Dundee 111 (http://www.drugdiscovery.dundee.ac.uk/). Primary screening identified 112 compounds that were active as co-therapies to potentiate the effect of 113 ceftazidime hydrate against B. thailandensis. Following hit confirmation and 114 potency determination, six compounds with IC 50 values < 10 µM were taken 115 forward in the study. We identified two compounds, A: 5,7-dichloroquinolin-8-ol 116 6 (also known as chloroxine) and B: 5-ethyl-5'-(2-hydroxyphenyl)-3'H-spiro [indole-117 3,2'-[1,3,4 ]thiadiazol]-2(1H)-one ( Figure 1 ), as promising hits for this indication. 118 7 Results 119 120
Assay development 121
The aim of this study was to identify compounds that may have use as co-122 therapies for the treatment phase of melioidosis. We aimed to develop an assay 123 that would identify compounds that reduced the proportion of B. thailandensis 124 cells that remained viable when delivered in combination with ceftazidime 125 hydrate (400 μg/ml, 100X MIC; large excess of MIC is generally used for assays 126 of antibiotic tolerant cell populations, e.g. [32] [33] [34] [35] ). We investigated a range of 127 absorbance, fluorescence, luminescence and qPCR based assays for 128 correlates of cell viability and evaluated the assay effectiveness using the Z' 129 statistic [36] commonly used for high-throughput screening (HTS) [37] . The 130 requirement of this initial assay was to distinguish a ceftazidime treated culture 131 from the negative controls with a Z' score greater than 0.4. A phenotypic cell 132 viability assay using the resazurin-based reagent PrestoBlue met this criterion, 133 resulting in a greater Z' score than the alternative assays (details of other 134 approaches investigated are described in Supplementary results). This offered 135 the opportunity for high throughput screening in a convenient and affordable 136 manner with good discrimination for the reduction in the survival of B. 137 thailandensis. A B. thailandensis culture, diluted in two-fold steps, and treated 138 with ceftazidime hydrate to simulate increasing levels of cell death, 139 demonstrated a clear reduction in the resazurin reduction signal when fewer 140 cells were present initially, indicating that the color change observed reflected 141 surviving cell numbers ( Figure 2 ). The assay was then optimized for use in 384 142 8 well plates with automated dispensing of reagents. The final assay quality was 143 determined, comparing B. thailandensis at the optimized test cell density in M9 144 media supplemented with ceftazidime hydrate, to heat killed bacteria in the 145 same media. The final assay resulted in a Z' score of 0.68 (Supplementary 146 Figure 1 ), which is consistent with an HTS requirement for a score of 0.5-0.7. 147
Controls included in the HTS protocol indicated that this assay quality was 148 maintained throughout the high throughput screening. these were down-selected due to known promiscuity issues. We selected 309 161 compounds for detailed screening: these included some near analogues to hits 162 from within the DDU collection that showed high activity and good 163 physiochemical properties. For these 309 compounds, a ten point, 2-fold, 164 concentration response assay was performed in duplicate (Supplementary 165 figure 2) with criteria for a positive hit set as greater than 50% inhibition at the 166 9 highest concentration tested (100 µM). Acceptable concentration response 167 relationships were returned for 58 compounds, of which 29 showed a pIC 50 (-168 log 10 (IC 50 )) values > 5, indicating at least 50% activity at 10 μM and that the 169 compound is a potential "hit". The experiments described above highlighted compounds that had activity on 186 cells that had survived following ceftazidime hydrate treatment. Our hypothesis 187 was that these compounds either potentiated the effects of ceftazidime hydrate, 188 or were toxic to cells in a metabolic state that rendered them insensitive to 189 ceftazidime hydrate. However, we reasoned that they might be acting as 10 antibiotics in their own right. We therefore determined the MIC for all six 191 compounds. Chloroxine demonstrated antimicrobial activity, with an MIC of 4 192 μg/mL (compared with 4-8 μg/mL for ceftazidime). This was not unexpected, as 193 chloroxine is known to be an effective antimicrobial with activity described Figure 6 ). This validates the activity of chloroxine. We also 211 performed a cytotoxicity assay that demonstrated that chloroxine was not toxic 212 to mammalian cells ( Supplementary Figure 4) . 213 214
Hit Expansion 215
One possibility was that chloroxine was acting non-specifically as an oxidizing 216 agent. Hit expansion using similar commercially available compounds was 217 therefore carried out to identify the neighboring structures of the hit compounds 218 to gain insight into the structure-activity relationship. This may also assist in the 219 future development of this compound from hit to lead. 220 221 Chloroxine (A: Figure 1 ) is a relatively small synthetic compound with limited 222 scope for improvement. The pIC 50 was determined as 5.5 using the PrestoBlue 223 assay ( Figure 4 ). A total of eleven similar compounds were commercially 224 available, and were used for this screen. None of these demonstrated 225 increased potency in the assay, as we had expected given the limited selection. 226
However, the pattern of loss of potency provides clear insights into how 227 chloroxine could be further modified. It was clear that the identity of the 228 substituent at the 7-position was important. Replacement of this with an amino 229 group significantly reduced activity (pIC 50 reducing to 3.4; Figure 7A ). Similarly, 230 addition of a methyl group at the 2-position was poorly tolerated, leading to a 231 loss of detectable activity at the concentrations tested ( Figure 7B ). The 232 halogens in the compound could also be altered to some extent. Replacement 233 of the chlorine atom with bromine at the 7-position was tolerated, but only if the 234 chlorine in the 5-position was also removed (reduction in pIC 50 from 5.5 to 5.1, 235 Figure 7C ). Two alternative structures with bromine were not active 236
( Supplementary Table 1 ). Iodide ions were also tolerated in place of the 237 chlorines, again with a small loss of activity ( Supplementary Table 1 ). More 238 12 extensive alterations to the structure of chloroxine resulted in the loss of at least 239 one order of magnitude of activity ( Supplementary Table 1 [20] , and this organism is resistant to several standard laboratory 272 antibiotics. It is easy to culture and grows well in standard media. These 273 properties allowed us to design a robust assay and transfer it between 274 laboratories without significant re-optimization or institutional barriers. 275 276 14 We decided that the use of a whole cell, phenotypic assay was advantageous 277 for this application. Cells in the low metabolic state that provide resistance to 278 antibiotics such as ceftazidime are heterogeneous [42] , and cover a range of 279 phenotypes. As such, a phenotypic assay focusing on the reductive state of the 280 cell was preferred over a target based assay for identifying tractable hit 281 compounds. In addition, phenotypic screening is regaining popularity over 282 target based screening. The principal reasons for this are that compounds with 283 the physiological ability to penetrate Gram-negative cells, function in vivo and 284 avoid efflux pumps are identified [43, 44] . Consequently, the compound series 285 obtained are likely to have significant advantages for downstream optimization 286 and development. The use of cell viability reagents, allowing the assessment of 287 cells at a population or individual level, offered the opportunity to identify viable 288 cells in a variety of states, and so was more relevant for our goals. Resazurin 289 based assays have previously been shown to identify all viable cells, and not 290 just the less abundant "persister" cells [45] . Other phenotypic assays that have 291 identified co-therapies against other organisms have exploited colony counting 292 [46, 47] , DNA binding dyes [48] and Live/Dead reagents [49] . The PrestoBlue 293 resazurin-based assay proved effective, in Burkholderia, at identifying 294 compounds that were active at concentrations below 10 μM, validating the 295 approach. Primary screening with the DDU's diversity library identified 2,127 296 compounds that showed a significant effect as a co-therapy with ceftazidime, 297 based on an activity threshold of 34.3% inhibition. The preliminary hit rate was 298 3.5%, which is in the expected range for an effective assay. 299 300 15
The assays described here identified chloroxine as a potential a co-therapy to 301 treat infection with B. pseudomallei. This compound demonstrated strong 302 activity in the primary assay (IC 50 = 2 μM), and resulted in a significant 303 reduction in the number of culturable cells following 24-48 hours treatment in 304 combination with ceftazidime (>1,000 fold reduction). This is similar to the level 305 of efficacy that has been previously observed with compounds targeting E. coli 306 [48] . It is hypothesized that chloroxine would reduce the proportion of cells 307 surviving ceftazidime treatment, and so reduce the intensive treatment phase. 308 chloroxine, has known bacteriostatic, fungistatic and antiprotozoal properties 309
[50] and has previously been shown to have synergistic effects with minocycline 310 against Pseudomonas aeruginosa [51] . Consistent with this, administration of 311 chloroxine alongside the frontline treatment for melioidosis, ceftazidime, had 312 better activity than either compound evaluated as a sole therapy. This suggests 313 that the compounds have complementary effects when treating B. 314 thailandensis. Bactericidal effects were observed at concentrations below the 315 chloroxine MIC. This study demonstrates evidence for the concept of use of 316 chloroxine as a complementary agent to ceftazidime against B. thailandensis. 317
318
Hit expansion was carried out for chloroxine. Only a limited range of compounds 319 around the chloroxine structure were available. None of the compounds 320 evaluated demonstrated improved activity compared to the parent compound 321 ( Supplementary Table 1 ). However, it became evident that only limited 322 substitutions at the chlorine positions were tolerated, only compounds with 323 other halides in these positions showed comparable activity to chloroxine 324 16 Furthermore, addition of a methyl group in the 2-position was sufficient to 325 abolish activity at the concentrations evaluated. This data strongly suggests that 326 chloroxine has some specificity, and is not a consequence of its suggested 327 oxidative activity, the addition of a methyl group would not be expected to 328 reduce the oxidative capability of chloroxine, yet this abolishes activity. 329 Furthermore, the iodo-equivalent of chloroxine retains similar activity to 330 chloroxine, and is considerably less oxidizing. This hit expansion validates 331 chloroxine as a co-therapy for ceftazidime. 332 Following the addition of PrestoBlue, plates were incubated at room 381 temperature for one hour and fluorescence was read at ex 540 / em 590 nm by 382 an Envision plate reader (PerkinElmer), or an Infinite M200 Pro (Tecan). All 383 liquid handling in the primary screen and hit expansion was automated. 384
19
An assay was developed to discriminate two-fold changes in cell numbers. A 385 bacterial culture was prepared as described above and serially diluted in an 386 equal volume of M9 media to produce two-fold dilutions. A positive control (cells 387 resuspended in M9 media without ceftazidime hydrate) and a negative control 388 (cells heat killed at 90 °C for 2 minutes) were included in these assays. Plates 389 were incubated at 37°C overnight before addition of PrestoBlue reagent and the 390 reading of fluorescence as described previously. 391 392 High throughput screening. 393 A library of 61,250 compounds was prepared as stock solutions in DMSO at a 394 concentration of 10 mM and supplied in 384-well Echo plates (Labcyte, #P-395 05525) for use in this screen. 45 µl of a culture resuspended in M9 media 396 supplemented with 400 μg/mL ceftazidime hydrate to an OD 600 nm of 0.8 397 (equivalent to late log phase growth, where ceftazidime is expected to be 398 effective) was added to give a final compound concentration of 30 μM. Plates 399 were covered with AeraSeal film (Sigma-Aldrich, #A9224) before incubation for 400 24 hours at 28 °C. A single point (SP) screen of all compounds was performed. 401 309 compounds from the diversity library were tested for potency using a 402 standard ten point half logarithm concentration response protocol [53] . 403
Selected hits were dispensed into 384 well Echo plates using the Biomek FX 404 automated liquid handling workstation (Beckman Coulter); two-fold serial 405 dilutions of each compound in DMSO was performed using an Echo 550 liquid 406 handler (Labcyte). 407 408 20 Our specifications for assay design stipulated a Z factor > 0. These were determined following the CLSI recommended protocol for 423 antimicrobial susceptibility testing via micro dilution method [55, 56] . 424 Experiments were initiated with an inoculum of ~10 5 cfu of B. thailandensis 425 E264, testing a concentration range from 0-1000 μM. Growth was detected by 426 absorbance at 600 nm using an Infinity M200 Pro plate reader (Tecan). 427
Synergistic interactions of chloroxine and ceftazidime were tested by mixing 428 equal volumes of media prepared using the micro dilution method, to test 429 21 concentrations of each antibiotic from 0-32 μg/ml. Samples were then treated 430 as above. 
